One of the most awaited abstracts of #ESMO26: OS results of the NataLEE trial
Adjuvant ribociclib provides statistically significant ⬆️ OS: delta of 1.2% at 60 months and 2.1% at 72 months (6-years)
Confirmed and sustained benefit in IDFS, DDFS and DRFS
@OncoAlert
996 views · 25 likes · 11 reposts · 3 replies
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- Gabriel Lazcano@gv_lazcano
@ElisaAgostinett @OncoAlert Pharma can't continue to offer expensive treatments with marginal benefits and expect nations to just go with it. We need to be more socially responsible too.
- Gabriel Lazcano@gv_lazcano
@ElisaAgostinett @OncoAlert This needs better patient selection. As a one size fits all, I don't think most healthcare systems would have a good time covering this. We recently added pembro for TN and the national budget has been consequently severely strained.
- Elisa Agostinetto@ElisaAgostinett
Simultaneous publication in @Annals_Oncology ‼️ https://www.annalsofoncology.org/article/S0923-7534(26)08640-0/fulltext @OncoAlert @myESMO
Source: Elisa Agostinetto · x.com